Abstract:Background BRD7 is a tumor suppressor known to inhibit cell proliferation and cell cycle progression and initiate apoptosis in breast cancer. However, the function and underlying molecular events of BRD7 in tumor invasion and metastasis in breast cancer are not fully understood. Methods BRD7 expression was assessed in two stable cell lines MDA231 and MCF7 with BRD7 overexpression and one stable cell line MDA231 with BRD7 interference using qRT-PCR and western blotting. CCK8 assay was used to examine the proliferation ability of MDA231 and MCF7 cells. Scratch wound healing assay was used to evaluate cell migration in MDA231 and MCF7 cells. Both Matrigel and three-dimensional invasion assays were performed to investigate the cell invasion ability after BRD7 overexpression or silencing or YB1 restoration in MDA231 and MCF7 cells. The potential interacting proteins of BRD7 were screened using co-immunoprecipitation combined with mass spectrometry and verified by co-immunoprecipitation in HEK293T cells. Additionally, we confirmed the specific binding region between BRD7 and YB1 in HEK293T cells by constructing a series of deletion mutants of BRD7 and YB1 respectively. Finally, xenograft and metastatic mouse models using MDA231 cells were established to confirm the effect of BRD7 on tumor growth and metastasis. Results Here, the results of a series of assays in vitro indicated that BRD7 has the ability to inhibit the mobility, migration and invasion of breast cancer cells. In addition, YB1 was identified as a novel interacting protein of BRD7, and BRD7 was found to associate with the C-terminus of YB1 via its N-terminus. BRD7 decreases the expression of YB1 through negatively regulating YB1 phosphorylation at Ser102, thereby promoting its proteasomal degradation. Furthermore, gene set enrichment analysis revealed that epithelial-mesenchymal transition (EMT) is the common change occurring with altered expression of either BRD7 or YB1 and that BRD7 represses mesenchymal genes and activates epithelial genes. Moreover, restoring the expression of YB1 antagonized the inhibitory effect of BRD7 on tumorigenicity, EMT, invasiveness and metastasis through a series of in vitro and in vivo experiments. Additionally, BRD7 expression was negatively correlated with the level of YB1 in breast cancer patients. The combination of low BRD7 and high YB1 expression was significantly associated with poor prognosis, distant metastasis and advanced TNM stage. Conclusions Collectively, these findings uncover that BRD7 blocks tumor growth, migration and metastasis by negatively regulating YB1-induced EMT, providing new insights into the mechanism by which BRD7 contributes to the progression and metastasis of breast cancer.

BRD7 Inhibits Enhancer Activity and Expression of BIRC2 to Suppress Tumor Growth and Metastasis in Nasopharyngeal Carcinoma

CircBRD7 Attenuates Tumor Growth and Metastasis in Nasopharyngeal Carcinoma Via Epigenetic Activation of Its Host Gene.

CircBRD7 inhibits tumor growth and metastasis in nasopharyngeal carcinoma via forming a positive feedback regulation loop with its host gene

BRD7 Suppresses the Growth of Nasopharyngeal Carcinoma Cells (HNE1) Through Negatively Regulating Β-Catenin and ERK Pathways

miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN/AKT pathway in nasopharyngeal carcinoma

BRD7 Expression and C-Myc Activation Forms a Double-Negative Feedback Loop That Controls the Cell Proliferation and Tumor Growth of Nasopharyngeal Carcinoma by Targeting Oncogenic Mir-141

BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways.

BRD7, a Novel Bromodomain Gene, Inhibits G1–S Progression by Transcriptionally Regulating Some Important Molecules Involved in Ras/mek/erk and Rb/E2F Pathways

The Developmental Transcription Factor IRF6 Attenuates ABCG2 Gene Expression and Distinctively Reverses Stemness Phenotype in Nasopharyngeal Carcinoma.

Growth Suppression of Nasopharyngeal Carcinoma Cell Through Transfection of BRD7 Gene

[Expression of BRD7-interacting Proteins,brd2 and BRD3, in Nasopharyngeal Carcinoma Tissues].

Promoter Methylation Inhibits BRD7 Expression in Human Nasopharyngeal Carcinoma Cells

Cloning and characterization of the BRD7 gene promoter.

[Researching a Novel NPC-related Candidate Suppressor Gene BRD7 by Two-Dimensional Gel Electrophoresis and MALDI-TOF-MS].

BRD7 Suppresses Invasion and Metastasis in Breast Cancer by Negatively Regulating YB1-induced Epithelial-Mesenchymal Transition

Stable Knockdown of ZBTB7A Promotes Cell Proliferation and Progression in Nasopharyngeal Carcinoma

EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression

Overexpression of E2F6 Gene Inhibits Promoter Activity of BRD7 Gene

Low BRMS1 Expression Promotes Nasopharyngeal Carcinoma Metastasis in Vitro and in Vivo and is Associated with Poor Patient Survival

Transcriptional regulation of BRD7 expression by Sp1 and c-Myc

B7‐H3 promotes nasopharyngeal carcinoma progression by regulating CD8+ T cell exhaustion